Similarly, treatments inhibiting IL-17 and IL-23, namely secukinumab and risankizumab, respectively, have been effective in managing the stubborn SAPHO syndrome [308,309], underscoring the role of the IL-17/Th17 pathway in acne pathology [85]. This evidence concerns the gene IL17A and acne.